• LAST PRICE
    30.3700
  • TODAY'S CHANGE (%)
    Trending Down-0.4500 (-1.4601%)
  • Bid / Lots
    12.1800/ 2
  • Ask / Lots
    48.7000/ 2
  • Open / Previous Close
    31.1100 / 30.8200
  • Day Range
    Low 30.2750
    High 31.4200
  • 52 Week Range
    Low 19.3450
    High 63.0825
  • Volume
    314,308
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 30.82
TimeVolumeMORF
09:32 ET183431.11
09:39 ET10031.075
09:41 ET10031.13
09:45 ET20031.42
09:48 ET20031.325
09:57 ET20031.15
09:59 ET10031.14
10:01 ET10031.06
10:06 ET10031
10:08 ET20030.955
10:10 ET30030.79
10:15 ET40030.81
10:17 ET60530.795
10:21 ET20030.93
10:24 ET40030.96
10:26 ET10030.91
10:32 ET28130.742
10:39 ET10030.87
10:46 ET20030.85
10:48 ET192530.72
10:50 ET139930.8
10:51 ET10030.83
11:02 ET22630.64
11:04 ET10030.63
11:06 ET20030.46
11:09 ET20030.58
11:15 ET10030.54
11:18 ET30030.535
11:20 ET26630.535
11:24 ET20030.57
11:26 ET20030.63
11:29 ET101030.625
11:33 ET20030.64
11:38 ET30030.64
11:40 ET110030.74
11:47 ET254830.8
11:51 ET10031.04
11:54 ET10030.865
11:58 ET23030.96
12:09 ET40030.94
12:14 ET120030.69
12:18 ET56230.69
12:20 ET10030.79
12:21 ET20030.85
12:23 ET10030.78
12:25 ET10030.85
12:34 ET20030.76
12:36 ET60030.72
12:38 ET10030.735
12:48 ET30030.79
12:52 ET10030.78
12:54 ET50030.81
12:56 ET36430.775
01:01 ET30030.8
01:03 ET25530.805
01:06 ET30030.7625
01:08 ET20030.825
01:10 ET11030.78
01:12 ET40030.86
01:14 ET10030.87
01:17 ET50030.89
01:19 ET106730.9375
01:21 ET40030.985
01:24 ET210031.06
01:26 ET20031.1
01:28 ET10031.14
01:30 ET360031.085
01:32 ET20031.07
01:33 ET64231.02
01:35 ET20030.94
01:37 ET20030.9
01:42 ET20030.87
01:46 ET30030.92
01:48 ET310030.94
01:50 ET10030.965
01:53 ET20030.9
01:55 ET42430.87
01:57 ET10030.77
02:02 ET20030.71
02:04 ET30030.705
02:08 ET41730.72
02:11 ET60030.74
02:13 ET10030.77
02:15 ET30030.79
02:18 ET10030.83
02:24 ET80030.87
02:26 ET10030.895
02:27 ET40030.84
02:31 ET60030.8
02:38 ET10030.8
02:40 ET370030.8
02:42 ET60030.8
02:44 ET100030.64
02:47 ET10030.665
02:49 ET30030.595
02:51 ET47130.54
02:54 ET30030.48
02:56 ET430030.375
02:58 ET20030.4
03:02 ET188130.46
03:03 ET333730.45
03:09 ET78830.53
03:12 ET10030.56
03:14 ET12130.555
03:16 ET53630.51
03:20 ET670030.37
03:21 ET10030.3
03:23 ET79430.34
03:25 ET30030.275
03:30 ET85830.32
03:32 ET11030.29
03:34 ET30030.37
03:36 ET30030.34
03:38 ET1023630.43
03:39 ET101730.58
03:41 ET10030.63
03:43 ET110030.53
03:45 ET50030.47
03:48 ET860030.52
03:50 ET10030.475
03:52 ET200430.4
03:54 ET197630.5
03:56 ET386130.46
03:57 ET464530.41
03:59 ET9698730.37
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesMORF
Morphic Holding Inc
1.5B
-8.7x
---
United StatesNMRA
Neumora Therapeutics Inc
1.5B
-4.1x
---
United StatesGPCR
Structure Therapeutics Inc
1.6B
-14.7x
---
United StatesKURA
Kura Oncology Inc
1.6B
-9.5x
---
United StatesBLTE
Belite Bio Inc
1.5B
-41.6x
---
United StatesSLNO
Soleno Therapeutics Inc
1.5B
-15.7x
---
As of 2024-05-31

Company Information

Morphic Holding, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company’s Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The Company is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). It has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.

Contact Information

Headquarters
35 GATEHOUSE DRIVE A2WALTHAM, MA, United States 02451
Phone
781-996-0955
Fax
302-655-5049

Executives

Independent Chairman of the Board
Gustav Christensen
President
Bruce Rogers
Chief Executive Officer, Director
Praveen Tipirneni
Chief Financial Officer, Chief Operating Officer
Marc Schegerin
Senior Vice President - Finance, Chief Accounting Officer
Robert Farrell

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.5B
Revenue (TTM)
$0.00
Shares Outstanding
50.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.49
EPS
$-3.49
Book Value
$14.01
P/E Ratio
-8.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.